PHARMACHON 2025 • SATURDAY, JULY 12 • SAN FRANCISCO, CA
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeSavarirayan, Ravi et al.Genetics in Medicine, Volume 26,…
Press release from ABNewswire The Key Achondroplasia Companies in the market include – BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin…
Boero, Silvio & Vodopiutz, Julia & Maghnie, Mohamad & Bergua, Josep & Ginebreda, Ignacio & Kitoh, Hiroshi & Langendörfer, Micha & Leiva-Gea, Antonio & Malone, Jason & McClure, Philip &…
This weekend, BioMarin, the Diamond Sponsor for the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, presented new data at the Pediatric Endocrine Society Meeting in Chicago. BioMarin announced positive…
SOURCE: Children’s National Hospital – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of…
via Murdoch Children’s Research Institute A drug that boosts bone growth in children with achondroplasia may also reduce their chances of sudden infant death syndrome (SIDS), sleep apnoea and needing…
